Skip To Main Content
Kala Visvanathan on Muck Rack

Kala Visvanathan

As seen in: Color Research & Application, Nature, Wiley Online Library, Therapeutic Advances in Medical Oncology, Annals of the Rheumatic Diseases, EurekAlert!, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Cancer Epidemiology, Biomarkers & Prevention, Healio and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kala

Contact Kala, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Biomarker-Based Eligibility for Lung Cancer Screening : Validation of the Protein-Based INTEGRAL-Risk Model

|
By Hana Zahed, Xiaoshuang Feng, Karine Alcala, Karl Smith-Byrne, Elham Khodayari Moez, Florence Guida, Demetrius Albanes, Stephanie J Weinstein, Alan A. Arslan, Qiuyin Cai, Xiao-Ou Shu, Wei Zheng, Chu Chen, Matthew Triplette, Lesley F Tinker, Arnulf Langhammer, Therese Haugdahl Nøst, Kristian Hveem, Roger Milne, Julie Bassett, Reza Malekzadeh, YING WANG, Alpa Patel, Kala Visvanathan, Jian-Min Yuan, Renwei Wang, Woon-Puay Koh, Howard D. Sesso, Xuehong Zhang, Mikael Johansson, Christopher I. Amos, Rayjean J. Hung, David Muller, David Müller, Hilary A Robbins, Mattias Johansson
| JAMA: Journal of the American Medical Association Verified
Biomarker-Based Eligibility for Lung Cancer Screening: Validation of the Protein-Based INTEGRAL-Risk Model Supplement 1. eTable 1. Cohorts and number of participants included in the training and testing set eTable 2. Precision (Inter coefficient of variation [CV] %) of protein measurements and blood levels observed in the training and testing datasets eTable 3. Number of outlier values for each protein in each cohort eTable 4.
Open in Who Shared Issue with article?

Circulating Vitamin D and Breast Cancer Risk: An International Pooling Project of 17 Cohorts

|
By Kala Visvanathan, Alison Mondul, Anne Zeleniuch-Jacquotte, Molin Wang
| Texas Medical Center
Abstract Laboratory and animal research support a protective role for vitamin D in breast carcinogenesis, but epidemiologic studies have been inconclusive. To examine comprehensively the relationship of circulating 25-hydroxyvitamin D [25(OH)D] to subsequent breast cancer incidence, we harmonized and pooled participant-level data from 10 U.S. and 7 European prospective cohorts. Included were 10,484 invasive breast cancer cases and 12,953 matched controls.
Open in Who Shared Issue with article?

Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk - British Journal of Cancer

|
By Yu Tian, Volker Arndt, D. Timothy Bishop, Hermann Brenner, Daniel Buchanan, Robert Carreras-Torres, Andrew Chan, Xuechen Chen, Stephen B. Gruber, Sophia Harlid, Michael Hoffmeister, Jeroen R. Huyghe, Susanna C. Larsson, Victor Moreno, Neil Murphy, Rami Nassir, Polly A. Newcomb, Shuji Ogino, Andrew J. Pellatt, Elizabeth A. Platz, Edward A Ruiz-Narvaez, Kala Visvanathan, Alicja Wolk, Li Chuan Hsu, Bens Pardamean, David Conti
| Nature Verified
Abstract Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk. We used data from 28,486 postmenopausal women (11,519 cases and 16,967 controls) of European descent.
Open in Who Shared Issue with article?
See all 34 licensed articles (35 Total)